PolarityTE Inc.

PolarityTE — Technical Presentation (July 2020)

14 slides from PolarityTE's technical presentation, Jul 27, 2020

  1. Slide 1: SkinTE in the Treatment of Diabetic Foot Wounds: Interim Analysis Topline Results

    @ Skinie SkinTE™ in the Treatment of Diabetic Foot Wounds NCT03881254 Interim Analysis Topline Results July 27, 2020

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc, (the “Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accurac

  3. Slide 3: Opening Remarks and Speakers

    @ SkiniE Opening Remarks David Seaburg, Chief Executive Officer Nikolai Sopko, MD, PhD, Chief Scientific Officer Speakers David Armstrong, DPM, MD, PhD (Study Chair) Lawrence DiDomenico, DPM (Study Investigator)

  4. Slide 4: Trial Design

    Trial Design Prospective, multi-center, randomized controlled trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone in the treatment of Diabetic Foot Ulcers (DFUs) Inclusion Criteria: + Wagner 1 Diabetic Foot Ulcer (DFU) extending at least through the dermis provided it is below the medi

  5. Slide 5: Trial Design: Primary Outcome Measure

    Trial Design Primary Outcome Measure + Percentage of wounds closed at 12 weeks defined as complete epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart Closure Determination + Initial closure determined by treating provider and confirmed

  6. Slide 6: Trial Design: Secondary Outcome Measures

    Trial Design Secondary Outcome Measures: Percent area reduction (PAR) at 4, 6, 8, and 12 weeks as measured by 3D digital planimetry (eKare, Fairfax, VA) Quality of life comparison using Wound Quality of Life Score at 12 weeks Pain assessment using the FACES pain scales at 12 weeks Peripheral neuropa

  7. Slide 7: Interim Analysis Trial Results

    @ SkiniE Interim Analysis Trial Results

  8. Slide 8: Interim Analysis: Demographics

    Interim Analysis: Demographics skinte soc ey Enrollment: FORTE SD, erate) Sate) osi_|+* 25 SkinTE patients and 25 SOC patients — 32.3 (7.56) 33.4(7.54) 059 * 13 sites across the US Male 18 (72) 1768) 076 Female 7 (28) 8(32) “Subject Comorbidities 9.6(3.29) 10.8 (6.15) 040 Key Demographics cesta easy

  9. Slide 9: Interim Analysis: SkinTE Met Primary Endpoint

    Interim Analysis: SkinTE Met Primary Endpoint Percentage of Wounds Closed 8 100 8 8 é ~-SkinTE -=SOC SkinTE Group: 18/25 DFUs Closed at 12 Weeks (72%) SOC Group: Fi 8/25 DFUs Closed at a —+— 12 Weeks (32%) SH = p=0.005 a= 0 2 4 6 8 10 12 Time (Weeks from Randomization)

  10. Slide 10: Percentage Area Reduction

    Percentage Area Reduction 8 8 8 Interim Analysis Secondary Endpoint: Percent Area Reduction (PAR) a ri rr -SkinTE SOC f x = = [ Z\ a el if iy V 0 2 4 6 8 Time (Weeks from Randomization) Week SkinTE soc p-value 4 78.6 (35.6) | 24.0 (106.52) | 0.00021 6 | 83.2 (40.89) | 43.8(101.98) | 0.004 8 | 86.6 (

  11. Slide 11: Interim Analysis: Secondary Endpoints

    Interim Analysis: Secondary Endpoints No Significant Difference * Quality of life comparison using Wound Quality of Life Score « Pain assessment using the FACES pain scales ¢ Peripheral neuropathy assessment using Semmes- Weinstein Monofilament "10"point discrimination test Cost of treatment - analy

  12. Slide 12: Interim Analysis: Adverse Events (AEs)

    Interim Analysis: Adverse Events (AEs) ¢ There were 77 AEs allocated to 24 subjects * The SkinTE group had 36 AEs allocated to 10 subjects ¢ SOC group had 41 AEs allocated to 14 subjects ¢ Final data is being source verified and subject to change

  13. Slide 13: Questions

    @ SkiniE Questions David Armstrong, DPM, MD, PhD Lawrence DiDomenico, DPM Nikolai Sopko, MD, PhD, Chief Scientific Officer Richard Hague, President & Chief Operating Officer

  14. Slide 14: About SkinTE

    2020 PolarityTE, ft About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient's own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparatio

PolarityTE — Technical Presentation (July 2020) on 6ix